All In Biotech

Drug Trial Radar · NCT07592910

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

A Phase 2, Open-label, Single-Arm Study of Mevrometostat Plus Enzalutamide in Metastatic Castration-Resistant Prostate Cancer Following Prior Androgen Receptor Pathway Inhibitor Therapy (MOMENT)

Last checked: Nov 20, 2026Latest source record: May 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Aug 2026

Primary completion

May 2029

Study completion Aug 2029

Sponsor

Lead sponsor
Prostate Cancer Clinical Trials ConsortiumAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer; Dana-Farber Cancer Institute; Fred Hutchinson Cancer Center
First posted
May 18, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to find out whether mevrometostat in combination with enzalutamide delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have previously received enzalutamide, darolutamide, or apalutamide in the metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC) setting but have not previously progressed on abiraterone.

Conditions

  • Metastatic Castrate Resistant Prostate Cancer (mCRPC)
  • Prostate Cancer (Adenocarcinoma)

Interventions

  • MevrometostatDrug

    875 mg oral tablet, taken twice daily with food

  • EnzalutamideDrug

    160 mg oral capsule, taken once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiographic progression free survival (rPFS)Time frame: From treatment initiation until documented disease progression, death, lost to follow-up, withdrawal, administrative censoring at the time of final analysis, whichever comes first, assessed up to 24 months.

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.